Stephens Reiterates "Overweight" Rating for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX - Get Free Report)'s stock had its "overweight" rating reissued by analysts at Stephens in a report released on Thursday,Benzinga reports. They presently have a $84.00 target price on the medical equipment provider's stock. Stephens' price objective points to a potential upside of 28.76% from the company's previous close.

A number of other analysts have also commented on HOLX. Needham & Company LLC lowered Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price for the company. in a research report on Monday, February 3rd. Morgan Stanley decreased their price target on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Wolfe Research initiated coverage on shares of Hologic in a research note on Friday, December 13th. They issued a "peer perform" rating on the stock. UBS Group increased their price objective on Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Finally, Raymond James upped their price target on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. Ten equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $85.77.

Hologic Trading Up 1.0 %

Shares of NASDAQ:HOLX traded up $0.66 during mid-day trading on Thursday, reaching $65.24. 3,019,983 shares of the company's stock were exchanged, compared to its average volume of 2,573,586. The firm has a market capitalization of $14.73 billion, a price-to-earnings ratio of 20.58, a PEG ratio of 2.14 and a beta of 0.97. Hologic has a twelve month low of $63.62 and a twelve month high of $84.67. The business's fifty day moving average price is $72.33 and its 200-day moving average price is $77.76. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.03 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, research analysts predict that Hologic will post 4.27 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.88% of the company's stock.

Hedge Funds Weigh In On Hologic

Several institutional investors have recently bought and sold shares of HOLX. Jensen Investment Management Inc. bought a new stake in shares of Hologic in the fourth quarter valued at $3,659,000. Corient Private Wealth LLC raised its stake in Hologic by 2.9% in the 4th quarter. Corient Private Wealth LLC now owns 53,306 shares of the medical equipment provider's stock valued at $3,843,000 after acquiring an additional 1,518 shares during the period. one8zero8 LLC purchased a new stake in Hologic during the fourth quarter valued at about $620,000. Frank Rimerman Advisors LLC boosted its position in Hologic by 9.5% during the fourth quarter. Frank Rimerman Advisors LLC now owns 5,427 shares of the medical equipment provider's stock worth $391,000 after purchasing an additional 472 shares during the period. Finally, Harrington Investments INC increased its stake in shares of Hologic by 10.0% in the fourth quarter. Harrington Investments INC now owns 14,320 shares of the medical equipment provider's stock worth $1,032,000 after purchasing an additional 1,307 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.